NuWave Investment Management LLC bought a new stake in Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 745 shares of the life sciences company’s stock, valued at approximately $273,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Capital Research Global Investors raised its position in shares of Illumina by 1.0% in the fourth quarter. Capital Research Global Investors now owns 7,986,271 shares of the life sciences company’s stock valued at $2,649,365,000 after purchasing an additional 78,667 shares during the period. Edgewood Management LLC raised its position in shares of Illumina by 1.7% in the first quarter. Edgewood Management LLC now owns 4,862,068 shares of the life sciences company’s stock valued at $1,327,928,000 after purchasing an additional 81,088 shares during the period. Nuveen Asset Management LLC raised its position in shares of Illumina by 6.6% in the fourth quarter. Nuveen Asset Management LLC now owns 2,468,093 shares of the life sciences company’s stock valued at $818,732,000 after purchasing an additional 153,459 shares during the period. Geode Capital Management LLC raised its position in shares of Illumina by 1.9% in the first quarter. Geode Capital Management LLC now owns 2,433,358 shares of the life sciences company’s stock valued at $663,379,000 after purchasing an additional 45,092 shares during the period. Finally, Norges Bank bought a new stake in shares of Illumina in the fourth quarter valued at approximately $647,840,000. 89.86% of the stock is currently owned by institutional investors.
In other news, SVP Susan H. Tousi sold 600 shares of the company’s stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $375.00, for a total value of $225,000.00. Following the completion of the sale, the senior vice president now owns 47,154 shares of the company’s stock, valued at approximately $17,682,750. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jay T. Flatley sold 4,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $370.22, for a total transaction of $1,480,880.00. Following the completion of the sale, the director now directly owns 230,933 shares of the company’s stock, valued at approximately $85,496,015.26. The disclosure for this sale can be found here. In the last three months, insiders sold 36,058 shares of company stock valued at $12,074,638. Corporate insiders own 0.38% of the company’s stock.
A number of analysts recently weighed in on the stock. Guggenheim lowered shares of Illumina from a “buy” rating to a “neutral” rating in a report on Tuesday, July 7th. Robert W. Baird lowered shares of Illumina from an “outperform” rating to a “neutral” rating and set a $310.00 target price on the stock. in a report on Tuesday, April 21st. Argus upped their target price on shares of Illumina from $340.00 to $380.00 in a report on Thursday, May 21st. JPMorgan Chase & Co. upped their target price on shares of Illumina from $340.00 to $390.00 and gave the stock an “overweight” rating in a report on Thursday, July 2nd. Finally, Barclays decreased their target price on shares of Illumina from $390.00 to $350.00 and set an “overweight” rating on the stock in a report on Thursday, March 26th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $340.50.
ILMN stock opened at $369.13 on Tuesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.10 and a quick ratio of 3.74. Illumina, Inc. has a one year low of $196.78 and a one year high of $384.21. The stock has a market cap of $54.43 billion, a PE ratio of 58.13, a P/E/G ratio of 5.48 and a beta of 1.00. The firm has a 50 day simple moving average of $362.04 and a two-hundred day simple moving average of $314.38.
Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.64 EPS for the quarter, topping the Zacks’ consensus estimate of $1.25 by $0.39. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $857.92 million. During the same quarter in the previous year, the company earned $1.60 EPS. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. On average, research analysts expect that Illumina, Inc. will post 6.15 EPS for the current fiscal year.
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
Further Reading: Conference Calls and Individual Investors
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.